Articles by Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP - Veterinary Healthcare
  • SEARCH:

ADVERTISEMENT

Articles by Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP


Articles
NSAIDS and cats: what do we know? (Proceedings)
May 1, 2011

The cat as a species represents a therapeutic challenge when trying to use NSAIDs safey, including the newer drugs. Nonsteroidal anti-inflammatory drugs block the first step of prostaglandin synthesis by binding to and inhibiting cyclooxygenase This action is both dose and drug dependent.

Transdermal gel delivery in cats: fuss or must? (Proceedings)
May 1, 2011

Compounded transdermal pluronic-lethicin organo (PLO) gels have become a popular method of drug delivery widely embraced by the veterinary profession, despite the lack of scientific evidence in support of this system. The PLO gels were developed as a practical alternative to traditional drug delivery systems.

Antimicrobial therapy and urinary tract infections: part 1-the other bad E. coli (Proceedings)
May 1, 2011

The advent of antimicrobial resistance is increasingly limiting therapeutic options in human and veterinary medicine. The ability of organisms to develop resistance to an antimicrobial varies with the species and strain.

Clinical pharmacology: use of package inserts and therapeutic decision making (Proceedings)
May 1, 2011

Today's drug package insert (DPI) can be a powerful ally in the selection and judicious use of a drug. The information that it provides might be categorized as either Product Description, Product Efficacy or Product Safety with some overlap among the categories. The order presented here may not be followed on the package insert. Paramount to understanding the use of a DPI is understanding what constitutes a PI.

Therapeutic drug monitoring (Proceedings)
May 1, 2011

The success of any fixed dosing regimen most often is based on the patient's clinical response to the drug. Fixed dosing regimens are designed to generate plasma drug concentrations (PDC) within a therapeutic range, ie, achieve the desired effect while avoiding toxicity.

Compounding and related issues (Proceedings)
May 1, 2011

Individualized drug therapy increasingly is being recognized as an important aspect of health care for both human and veterinary medicine. Consequently, veterinarians must reach beyond FDA-approved veterinary products to provide the current standard of veterinary care to their patients.

Antimicrobials and UTIs: part 2- antimicrobial options (Proceedings)
May 1, 2011

Treatment of urinary tract infections offer an example of the hazards and difficulties encountered when initial response is insufficient. Treatment of bacterial UTI offers a good example of how treatment of bacterial infections might be approaches. The goal of drug therapy has been to eliminate bactiuria, but this goal should be modified to include eradication of infection while minimizing the advent of resistance.

Antimicrobials and UTIs: part 3-building the dosing regimen (Proceedings)
May 1, 2011

Dosing regimens for antimicrobials should be related to MIC. However, simply achieving the MIC in the patient is not likely to be sufficient for a variety of reasons.

Compounding issues: quality, safety, and efficacy (Proceedings)
May 1, 2011

Individualized drug therapy increasingly is being recognized as an important aspect of health care for both human and veterinary medicine. Consequently, veterinarians must reach beyond FDA-approved veterinary products to provide the current standard of veterinary care to their patients.

ADVERTISEMENT

Click here